Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 1, 2002 - Issue 2
Submit an article Journal homepage
231
Views
49
CrossRef citations to date
0
Altmetric
Review

The rational use of potentially hepatotoxic medications in patients with underlying liver disease

James H Lewis Division of Gastroenterology, Director of Hepatology, Georgetown University Medical Center, Washington, DC 20007-2197, USA. [email protected]
Pages 159-172 | Published online: 23 Feb 2005

Bibliography

  • Physicians' Desk Reference 56th edn (2002). Medical Economics Company, Inc., Montvale, USA.
  • ZIMMERMAN HJ: Hepatotoxicio,. The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd edh). Lippincott Williams & Wilkins, Philadelphia (1999).
  • ••The premier reference text on drug-inducedliver disease.
  • LARREY D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis. (2002) 22:145–155.
  • ••An excellent overview on causalityassessment in drug-induced liver disease.
  • REICHEN J: Prescribing in liver disease. Hepatol (1997) 26\(Suppl. 1):36–40.
  • FARRELL GC: Drug-induced Liver Disease. Churchill-Livingstone, London (1994).
  • MARINO G, ZIMMERMAN HJ, LEWIS JH: Management of drug-induced liver disease. Carr. Gastroenterol Rep. (2001) 3:38–48.
  • •Discusses the current approach to avoiding and treating drug-induced liver disease.
  • LEWIS JH: Drug-induced liver disease. Med. Clin. North Am. (2000) 84:1275–1311.
  • NEUBERGER J, WILLIAMS R: Halothane anesthesia and liver damage. Br. Med. (1984) 289:1136–1139.
  • PATEL T: Surgery in the patient with liver disease. Mayo Clin. Proc. (1999) 74:593–599.
  • KNOWLES SR, SHAPIRO LE, SHEAR NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Sal (1999) 21:489–501.
  • •Defines this increasingly recognised inimunoallergic-mediated clinical syndrome that primarily affects children.
  • BRYANT AE III, DREIFUSS FE: Valproic acid hepatic fatalities: III. US experience since 1986. Neurology(1996) 46:465–469.
  • PELLOCK JM: Felbamate in epilepsy therapy: evaluating the risks. Drug Sal (1999) 21:225–239.
  • LEWIS JH, ZIMMERMAN HJ: Drug- and chemical-induced cholestasis. Clin. Liver Dis. (1999) 3:433–464.
  • LEWIS JH: NSAID-induced hepatotoxicity. Clin. Liver Dis. (1998) 2:543–561.
  • BANKS AT, ZIMMERMAN HJ, ISHAK KG et al.: Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration. Hepatology (1995) 22:820–825.
  • TARAZI EM,HARTER JG, ZIMMERMAN HJ et al.: Sulindac-associated hepatic injury. Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology (1993) 104:569–574.
  • LAFFI G, LAVILLA G, PINZANI M et al.: Arachidonic acid derivatives and renal function in liver cirrhosis. &min. Nephrol. (1997) 17:530–548.
  • DELEDINGHEN V, HERESBACH D, FOURDAN O et al: Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut (1999) 44:270–273.
  • GITLIN N: Salicylate hepatotoxicity. The potential role of hypoalbuminemia.f Clin. Gastroenterol (1980) 2:883–884.
  • RILEY TR, SMITH JP: Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am. Gastroenterol (1998) 93:1563–1565.
  • VALE JA, PROUDFOOT AT: Paracetamol (acetaminophen) poisoning. Lancet (1995) 346:547–552.
  • BENSON GD: Acetaminophen in chronicliver disease. Clin. Pharmacol Ther. (1983) 33:95–101.
  • ZIMMERMAN HJ, MADDREY WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology (1995) 22:767–773.
  • ••One of the seminal papers defining theinteraction between APAP and alcohol producing fulminant hepatitis from therapeutic doses.
  • KUFFNER EK, DART RC, BOGDAN GM et al: Effect of maximum daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. (2001) 161:2247–2252.
  • •This study purports to demonstrate the safe use of APAP with alcohol but has several methodological flaws as brought out by a number of commentators (see [25,26]).
  • HOLTZMAN JL: The effect of alcohol on acetaminophen hepatotoxicity (letter). Arch. Intern. Med. (2002) 162:1193.
  • OVIEDO J, WOLFE MM: Alcohol, acetaminophen, and toxic effects on the liver. Arch. Intern. Med. (2002) 162:1194-1195. Letter.
  • SCHMIDT LE, DALHOFF K, POULSEN HE: Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology (2002) 35:876–882.
  • ••An important study demonstrating that therisk of APAP hepatic necrosis is highest for chronic alcohol users compared to acute alcohol ingestion.
  • BOHAN A, BOYER JL: Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis. (2002) 22:123–136.
  • STIEGER B, FATTINGER K, MADON J et al.: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology (2000) 118:422–430.
  • MORRISON AS, JICK H, ORY HW: Oral contraceptives and hepatitis. A report from the Boston Collaborative Drug Surveillance Program. Lancet (1977) 1:1142–1143.
  • SCHWEITZER IL, WEINER JM, MCPEAK CM et al.: Oral contraceptives in acute viral hepatitis. JAMA (1975) 233:979–980.
  • PYMAR HC, CREININ MD: The risks of contraceptive pills. Semin. Reprod. Med. (2001) 19:305–312.
  • FARRELL GC: Drugs and steatohepatitis. Semin. Liver Dis. (2002) 22:185–194.
  • MOFFAT DF, OIEN KA, DICKSON J et al.: Hepatocellular carcinoma after long-term tamoxifen therapy. Ann. Oncol. (2000) 11:1195–1196.
  • SMITH LL, BROWN K, CARTHEW P et al.: Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit. Rev. Toxicol. (2000) 30:571–594.
  • FRIEDMAN G, LAMOUREUX E, SHERKER AH: Fatal fulminant hepatic failure due to cyproterone acetate. DV. Dis. Sci. (1999) 44:1362–1363.
  • ANDRADE RJ, LUCENA MI, FERNANDEZ MC et al: Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet (1999) 353:983.
  • PU YS, LIU CM, KAO JH et al: Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur. Urol. (1999) 36:293–297.
  • FAICH GA, MOSELEY RH: Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Sal: (2001) 10:537–547.
  • ••A comprehensive review of troglitazonehepatotoxicity with an important analysis of alleged cases illustrating the difficulties that exist in proving causation.
  • LEBOVITZ HE, KREIDER M, FREED MI: Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care (2002) 25:815–821.
  • •Summarises the clinical trials experience with rosiglitazone showing the lack of any significant hepatic injury with this agent compared to troglitazone.
  • LENHARD MJ, FUNK WB: Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. Diabetes Care (2001) 24:168–169.
  • CALDWELL SH, HEAPENHEIDE EE, REDICK JA et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. (2001) 95:519–525.
  • GRAHAM DJ, DRINKARD CR, SHATIN D et al.: Liver enzyme monitoring in patients treated with troglitazone. JA/VIA (2001) 286:831–833.
  • •A study based on a sample of claims data from a large health maintenance organisation found that liver enzyme monitoring was not performed as recommended in most patients receiving troglitazone prior to its withdrawal, despite progressively strict warnings by the FDA and the manufacturer.
  • KOBAYASHI M, HIGASHIYAMA S, NAGAKIRI S et al.: A case of drug-induced liver injury with positive LE phenomenon caused by mercazole. Acta Hepatol. Jpn. (1981) 22:1453.
  • LIAW Y, HUANG M, FAN K et al.: Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: a cohort study. Ann. Intern. Med. (1993) 118:424
  • BROWN SJ, DESMOND PV: Hepatotoxicity of antimicrobial agents. Semin. Liver Dis. (2002) 22:157–167.
  • LEWIS JH, ZIMMERMAN HJ, BENSON GD et al.: Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology (1984) 86:503–513.
  • CHIEN RN, YANG LJ, LIN PY et al: Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology (1997) 25:103–107.
  • LAZARCZYK DA, GOLDSTEIN NS, GORDON SC: Trovafloxacin hepatotoxicity. Dig. Dis. Sci. (2001) 46:925–926.
  • MONTANARO A: Sulfonamide allergy. Immunol. Allergy Clin. North Am. (1998) 18:843–849.
  • BLACK M, MITCHELL JR, ZIMMERMAN HJ et al.: Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 69:289–302.
  • MITCHELL I, WEND ON J, FITT S et al.:Anti-tuberculous therapy and acute liver failure. Lancet (1995) 345:555–556.
  • DURAND F, BERNUAU L, PESSAYER D et al: Deleterious influence of pyrazinamide on the outcome of patients with fulminant or sub-fulminant liver failure during antituberculous treatment including isoniazid. Hepatology (1995) 21:929–932.
  • HUANG Y-S, CHERN H-D, SU W-J et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 35:883–889.
  • ••This study demonstrates an increased risk ofisonazid liver injury in slow acetylators in an Asian population; previous studies had been equivocal.
  • OZICK LA, JACOB L, COMER GM et al: Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am. J. Gastroenterol. (1995) 90:1978–1980.
  • UNGO JR, JONES D, ASHKIN D et al.: Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am. J. Resp. Crit. Care Med. (1998) 157:1871–1876.
  • •This study demonstrates a higher risk of anti-TB therapy in patients coinfected with chronic viral hepatitis and/or HIV.
  • WONG WM, WU PC, YUEN MF et al: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 31:201–206.
  • •This study demonstrates a higher risk of anti-TB therapy in patients coinfected with chronic viral hepatitis and/or HIV.
  • SADAPHAL P, ASTEMBORSKI J, GRAHAM NM et al.: Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin. Infect. Dis. (2001) 15:1687–1691.
  • SAIGAL S, AGARWAL SR, NANDEESH HP et al.: Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. ./. Gastroenterol. Hepatol. (2001) 16:1028–1032.
  • SALPETER SR, SANDERS GD, SALPETER EE et al.: Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann. Inter. Med. (1997) 127:1051–1061.
  • DURAND F, JEBRAK G, PESSAYRE D et al.: Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Sal (1996) 15:394–405.
  • LEWIS JH, ZIMMERMAN HJ: Tuberculosis of the liver, and biliary tract. In: Tuberculosis and Nontuberculous Mycobacterial Infections (4th edni. Schlossberg D (ed.), WB Saunders Company, Philadelphia (1999):238–263.
  • SCHEUER PJ, LAS S, SUMMERFIELD JA et al: Rifampicin hepatitis. A clinical histological study. Lancet (1974) 1:421–425.
  • BACHS L, PARES A, ELENA M et al.: Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology (1992) 102:2077–2080.
  • PODESTA A, LOPEZP, TERG R et al.: Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig. Dis. ScL (1991) 36:216–220.
  • MCKENZIE R, FRIED MW, SALLIE R et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl. J. Med. (1995) 333:1099–1105.
  • ORMSETH EJ, HOLTZMULLER KC, GOODMAN ZD et al.: Hepatic decompensation associated with lamivudine: a case report and review of lamivudine-induced hepatotoxicity. Am. Castroenterol (2001) 96:1619–1622.
  • PRAKASH M, POREDDY V, TIYYAGURA L et al.: Jaundice and hepatocellular damage associated with nevirapine therapy. Jim. .1 Castroenterol (2002) 96:1571–1574.
  • SULKOWSKI MS, THOMAS DL, CHAISSON RE et al.: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. "AMA (2000) 283:74–80.
  • •A seminal paper demonstrating an increased risk of antiretroviral therapy-associated hepatic injury among HIV patients co-infected with chronic viral hepatitis.
  • MCGOVERN B, BICA I: Risk of HAART therapy in hepatitis C. Hepatology (2002) 35:730.
  • VELASCO M, GUIJARRO C: Elevated liver enzymes following initiation of antiretroviral therapy. "AMA (2000) 283:2526–2527.
  • SORIANO V, SULKOWSKI M, BERGIN C et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 16:813–828.
  • BALZARINI J, LEE C, HERDEWIJN P et al.: Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. (1991) 266:21509–21514.
  • DALTON T, BERRY R: Hepatotoxicity associated with sustained-release niacin. Am. Med. (1992) 93:1992.
  • HENWOOD JM, HEEL RC: Lovastatin. A preliminary review of its pharmacodymanic properties and therapeutic use in hyperlipidemia. Drugs (1988) 36:429–454.
  • KORNBRUST DJ, MACDONALD JS, PETER CP et al.: Toxicity of the HMG-Coenzyme A reductase inhibitor, lavastatin, to rabbits. J. Pharmacol Exp. Ther. (1989) 248:498–505.
  • •The authors demonstrated that hepatic injury from lovastatin could be prevented by giving experimental animals mevalonic acid; suggesting that injury from the HMG-CoA reductase inhibitors was more of a pharmacological effect rather than direct pathological toxicity.
  • KNOPP RH: Drug treatment of lipid disorders. N Engl. I Med. (1999) 341:498–511.
  • TOLMAN KG: Defining patient risks from expanded preventive therapies. Am. J. Cardiol (2000) 85(12 Suppl. 1):15E–19E.
  • ••An excellent review concluding that the riskof liver injury from HMG-CoA reductase inhibitors is very low; the author argues that monitoring liver enzymes in these patients is unnecessary.
  • UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Sal (2000) 22:441–457.
  • FARMER JA, TORRE-AMIONE G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Sal (2000) 23:197–213.
  • IMAGAWA DK, DAWSON 5111, HOLT CD et al.: Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation (1996) 62:934–942.
  • KURIHARA T, AKIMOTO M, ABE K et al.: Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. The]: (1993) 15:890–898.
  • ROBERTS WC: Safety of fenofibrate - USand worldwide experience. Cardiology (1989) 76:169–179.
  • CLARK JA, ZIMMERMAN HJ, TANNERLA: Labetalol hepatotoxicity. Ann. Intern. Med. (1990) 113:210–213.
  • RODMAN JS, DEUTSCH DJ, GUTMAN SI: Methyldopa hepatitis: a report of six cases and review of the literature. Am. J. Med. (1976) 60:941-948. LEWIS JH, RANARD RC, CARUSO A et al: Amiodarone hepatotoxicity: prevalence and clinico-pathologic correlations among 104 patients. Hepatology (1989) 9:679–685.
  • ARCIDI JM, MOORE GW, HUTCHINS GM: Hepatic morphology in cardiac dysfunction: a clinicopathologic study of 1000 subjects at autopsy. Am. J. Pathol (1981) 104:159–166.
  • WATKINS PB, ZIMMERMAN HJ, KNAPP HJ et al: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. "AMA (1994) 271:992–998.
  • LEWIS JH, SCHIFF ER: Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am. J. Castroenterol (1988) 88:1337–1345.
  • ZACHARIAE H: Liver biopsies and methotrexate. A time for reconsideration?" Am. Acad. Dermatol (2000) 42:531–534.
  • LEWIS JH: Monitoring for methotrexate hepatotoxicity in patients with rheumatoid arthritis: another hepatologist's perspective. Rheumatol (1997) 24:1459–1460.
  • RAVELLI A, MIGLIAVACCA D, VIOLAS et al.: Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin. Exp. Rheumatol (1999) 17:625–627.
  • SAFER DJ, ZITO JM, GARDNER JE: Pemoline hepatotoxicity and postmarketing surveillance. I Am. Acad. Child Adolesc. Psychiatry (2001) 40:622–629.
  • ASSAL F, SPAHR L, HADENGUE A et al.: Tolcapone and fulminant hepatitis. Lancet (1998) 354:958.
  • MITCHELL JE: Naltrexone and hepatotoxicity. Lancet (1986) 1:1215.
  • BASHIR RM, LEWIS JH: Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Castroenterol Clin. North kn. (1995) 24:937–967.
  • WRIGHT C IV, VAFIER JA, LAKE CR: Disulfiram-induced fulminant hepatitis: guidelines for liver-panel monitoring. J. Clin. Psychiatry (1988) 49:430–434.
  • ROTOLO FS, BRANUM CD, BOWERS BA et al.: The effect of cyclosporin on bile secretion in rats. Am.j Surg. (1986) 151:35–40.
  • GEUBEL AP, DEGALOCSY C, ALVES N et al.: Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology (1991) 100: 1701-1709.
  • SCHUPPAN D, JIA J-D, BRINKHAUS B et al.: Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology (1999) 30:1099–1104.
  • SEEFF LB, LINDSAY KL, BACON BR et al.: Complementary and alternative medicine in chronic liver disease. Hepatology (2001) 34:595–603.
  • STEDMAN C: Herbal hepatotoxicity. Seinin. Liver Dis. (2002) 22:195–206.
  • ••Summary of a recent NIH-sponsoredconference on the use of alternative therapies in chronic liver disease.
  • DELEVE LD, SHULMAN HM, MCDONALD GB: Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Seinin. Liver Dis. (2002) 22:27–42.
  • ••An excellent overview of liver toxicity fromherbal products.
  • THE WASHINGTON POST: FDA warning on dietary herb. July 7 2001:A5.
  • OLUKOGA A, DONALDSON D: Liquorice and its health implications. Roy Soc. Health (2000) 120:83–89.
  • LEWIS JH: Licorice for hepatitis C: yum-yum or just ho-hum? kn. Gastroenterol (2001) 96:2291–2292.
  • KAPLOWITZ N: Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology (2001) 33:308–310.
  • MEYER UA: Pharmacogenetics and adverse drug reactions. Lancet (2000) 356:1667–1671.
  • PHILLIPS KA, VEENSTRA DL, OREN E et al: Potential role of pharmacogenetics in reducing adverse drug reactions: a systemic review. JAMA (2001) 286:2270–2279.
  • AITHAL GP, RAWLINS MD, DAY CP: Accuracy of hepatic adverse drug reaction reporting in one English health region. Br. Med. (1999) 319:1541.
  • AITHAL GP, RAWLINS MD, DAY CP: Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. Hepatol (2000) 33: 949–952
  • LUCENA MI, CAMARGO R, ANDRADE RI et al.: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 33:123–130.
  • LEE WM: Assessing causality in drug-induced liver injury. Hepatol (2000) 33:1003–1005.
  • MARCHESINI G, BRIZI M, BIANCHI G et al.: Metformin in non-alcoholic steatohepatitis. Lancet (2001) 358:893–894.
  • JONSSON JR, CLOUSTON AD, ANDO Y et al.: Angiotensin converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology (2001) 121:148–155.

Websites

  • http://www.fda.gov/cder/livertox/ prevention/im0093/rfld002.htm
  • http://www.fda.gov/ohrms/dockets/ac/ cder00.html Joint meeting of the FDA, Non-prescription Drugs Advisory Committee and Endocrinology and Metabolic Drugs Advisory Committee. (July 13–14) 2000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.